© 2023 HSP News Service, L.L.C.
In a Chinese single-center, retrospective cohort, propensity score–matched analysis reported in JAMA Surgery, Wan et al found no difference in long-term outcomes, including distant metastasis–free and overall survival, with minimal-access breast surgery vs conventional breast surgery in women with...
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
In a single-center retrospective cohort study reported in JAMA Network Open, Titan et al identified the proportion of women with a history of smoking undergoing breast cancer screening with mammography who were eligible for low-dose computed tomography (CT) lung cancer screening, as well as the...
As reported in The Lancet Oncology by François-Clément Bidard, MD, and colleagues, the French phase III PADA-1 trial has shown that switching to fulvestrant/palbociclib vs continuing first-line aromatase inhibitor (AI)/palbociclib therapy was associated with improved progression-free survival among ...
As reported in the Journal of Clinical Oncology by Carroll et al, an analysis from the Thinking and Living with Cancer Study has shown higher levels of C-reactive protein (CRP) at baseline and during follow-up among women with stage 0 to III breast cancer diagnosed at age ≥ 60 years vs controls,...
Although breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die of the disease, despite a lower incidence, according to findings outlined in the American Cancer Society’s report Breast Cancer Statistics, 2022, and a companion study published by ...
Just 1 month after the DESTINY-Breast04 data were presented at the 2022 ASCO Annual Meeting Plenary Session,1 an ASCO expert panel released updated guidance that endorses the adoption of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) into clinical practice for patients with...
TROPiCS-02 is a statistically positive trial, with the primary endpoint met and also now with an overall survival gain of 3.2 months,” said the study’s invited discussant Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology, Barcelona. “TROPiCS-02 is...
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in women with previously treated, hormone receptor–positive/HER2-negative, locally recurrent, inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial.1 The...
After my first breast cancer diagnosis, in 2010, the odds for a cure were seemingly all weighted in my favor. A routine mammogram screening had picked up a small—less than 1 cm—mass in my right breast, and a tissue biopsy confirmed it was stage I estrogen receptor–positive breast cancer. I had no...
In a Swedish study reported in JAMA Network Open, Gahm et al found that multiple vs single doses of prophylactic intravenous (IV) antibiotics did not significantly reduce the risk of surgical site infection leading to implant removal in women undergoing implant-based breast reconstruction after...
As reported in the Journal of Clinical Oncology by Ji et al, the HOPE study (Hurria Older Patients [HOPE] with Breast Cancer Study) has shown that older women categorized as robust prior to adjuvant chemotherapy are at risk for clinical decline postchemotherapy, with high baseline levels of the...
In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...
In a case-control study within the U.S. Women’s Health Initiative (WHI) study population reported in JAMA Oncology, Lønning et al found that BRCA1 promoter methylation identified in white blood cells was associated with increased risks of incident triple-negative breast cancer and high-grade serous ...
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
In a National Cancer Database (NCDB) analysis reported in a research letter in JAMA Oncology, Bazan et al found that Hispanic ethnicity was reported in patient demographics or results in less than half of studies in breast cancer, with a smaller proportion categorizing race and ethnicity into...
A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ovarian tissue cryopreservation in those not eligible for gamete cryopreservation); ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy; and long-term follow-up to improve the management of gynecology-related issues faced by these women.
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in patients with previously treated hormone receptor–positive/HER2-negative locally recurrent inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial. These...
Patients who received fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low metastatic breast cancer reported that the treatment maintained their quality of life compared to conventional chemotherapy, according to results presented by Ueno et al at the European Society for Medical Oncology (ESMO)...
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the phase III TROPiCS-02 trial has shown a significant progression-free survival benefit with sacituzumab govitecan-hziy vs chemotherapy in previously treated patients with hormone receptor (HR)-positive,...
In a research letter in JAMA Oncology, Sullivan et al described details of postmarketing cases of noninfectious colitis in patients with breast cancer reported to the U.S. Food and Drug Administration that were considered possibly or probably related to alpelisib treatment. Key Findings A total of...
Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...
In a Swedish nationwide prospective cohort study reported in JAMA Oncology, Marklund et al found no increased risk of relapse or disease-specific mortality among women undergoing fertility preservation with or without hormonal stimulation at the time of breast cancer diagnosis. Study Details The...
Women with a breast cancer diagnosis undergoing procedures for fertility preservation are not at an increased risk for recurrence of the disease or disease-specific mortality, according to the results of a study from the Karolinska Institutet in Sweden that followed participants for 5 years on...
Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...
As reported in the Journal of Clinical Oncology by Offersen et al, the phase III Danish Breast Cancer Group Partial Breast Irradiation Trial showed that partial-breast irradiation was noninferior to whole-breast irradiation in terms of the risk for breast induration in women aged ≥ 60 years...
As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...
In a population-based retrospective cohort study reported in JAMA Network Open, Sood et al found that longer time to adjuvant endocrine therapy initiation in Medicaid-insured women with breast cancer was associated with a reduced likelihood of short- and long-term adherence to treatment. As stated...
In the phase Ib DS8201-A-U105 trial, the addition of the PD-1 inhibitor nivolumab to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) did not appear to improve outcomes over T-DXd alone (based on historical controls). However, it did establish the safety of the combination,...
On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu), an intravenous infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy targeted to patients with the...
As reported in the Journal of Clinical Oncology by Johansson et al, 20-year follow-up of the Stockholm trial (STO-5) has shown long-term reduction in the risk of distant recurrence with 2 years of adjuvant endocrine therapy with goserelin and tamoxifen vs no endocrine therapy in premenopausal women ...
A study released by the University of Colorado Cancer Center showed that more than 70% of patients with breast cancer have reported changes that affect their sexual health during and beyond treatment. The study was published by Huynh et al in the Annals of Surgical Oncology. Study Background “More...
Black women are twice as likely to be diagnosed with triple-negative breast cancer compared with White women, 28% more likely to die from the disease than White women, and are less likely to be treated with surgery and chemotherapy, according to a study published in 2021. Despite these statistics,...
In a Latin American phase III trial reported in the Journal of Clinical Oncology, Hope S. Rugo, MD, and colleagues found that oral paclitaxel with the P-glycoprotein pump inhibitor encequidar produced a higher response rate and trends toward better survival outcomes vs intravenous (IV) paclitaxel...
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III KEYNOTE-355 trial has shown improved overall survival with the addition of pembrolizumab to chemotherapy in previously untreated patients with advanced triple-negative breast cancer with a...
The final overall survival analysis of the phase III PALOMA-2 trial has shown no significant benefit for palbociclib given with letrozole, vs letrozole and placebo, as a first-line treatment in hormone receptor–positive, HER2-negative metastatic breast cancer.1 The results were reported at the 2022 ...
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer, just 4 years after the previous practice guideline update was released in 2018.1,2 This latest update reviews results from multiple clinical trials published between 2016 and 2021 that...
For some patients aged 55 or older with early-stage, low-risk breast cancer, endocrine therapy following breast-conserving surgery may be sufficient without the need for postoperative radiation therapy, according to the results of the prospective LUMINA trial, reported at the 2022 ASCO Annual...